# antibodies -online.com





# anti-TRAIL antibody (AA 95-281)

1 Image

2

**Publications** 



Go to Product page

#### Overview

| Quantity:            | 0.1 mg                               |
|----------------------|--------------------------------------|
| Target:              | TRAIL (TNFSF10)                      |
| Binding Specificity: | AA 95-281                            |
| Reactivity:          | Human                                |
| Host:                | Mouse                                |
| Clonality:           | Monoclonal                           |
| Conjugate:           | This TRAIL antibody is un-conjugated |
| Application:         | Flow Cytometry (FACS)                |

## **Product Details**

| Immunogen:                  | Recombinant soluble fragment (aa 95-281) of human TRAIL.   |
|-----------------------------|--|
| Clone:                      | 2E5  |
| Isotype:                    | lgG1   |
| Specificity:                | The antibody 2E5 reacts with an extracellular epitope within C-terminal half of TRAIL (APO-2L), a 21 kDa cytotoxic protein, activator of rapid apoptosis in tumor cells. TRAIL is mainly expressed in spleen, lung, prostate and also in many other tissues. |
| No Cross-Reactivity:        | Mouse  |
| Cross-Reactivity (Details): | Human  |
| Purification:               | Purified by protein-A affinity chromatography.   |
| Purity:                     | > 95 % (by SDS-PAGE)   |

#### **Target Details**

| Target:           | TRAIL (TNFSF10)   |
|-------------------|---|
| Alternative Name: | CD253 / TRAIL (TNFSF10 Products)  |
| Background:       | TNF superfamily member 10,Human CD253 / TRAIL (TNF-related apoptosis inducing ligand), also called Apo2, is a type II membrane protein from the TNF family. TRAIL is a cytotoxic protein which activates rapid apoptosis in tumor cells, but not in normal cells. TRAIL-induced apotosis, is achieved through binding to two dealth-signaling receptors, DR4 (CD261 / TRAIL-R1) and DR5 (CD262 / TRAIL-R2).,TRAIL, Apo-2 ligand, Apo-2L, TNFSF10, APO2L, TNLG6A |
| Gene ID:          | 8743  |
| UniProt:          | P50591  |
| Pathways:         | Apoptosis, Positive Regulation of Endopeptidase Activity  |

#### **Application Details**

| Application Notes: | Flow cytometry: Recommended dilution: 1-5 μg/mL. |
|--------------------|--|
| Restrictions:      | For Research Use only                            |

#### Handling

| Concentration:     | 1 mg/mL  |
|--------------------|--|
| Buffer:            | Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide  |
| Preservative:      | Sodium azide   |
| Precaution of Use: | This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only. |
| Storage:           | 4 °C   |
| Storage Comment:   | Store at 2-8°C. Do not freeze.   |

#### **Publications**


Product cited in:

Hyer, Croxton, Krajewska, Krajewski, Kress, Lu, Suh, Sporn, Cryns, Zapata, Reed: "Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells." in: **Cancer research**, Vol. 65, Issue 11, pp. 4799-808, (2005) (PubMed).

Plasilova, Zivny, Jelinek, Neuwirtova, Cermak, Necas, Andera, Stopka: "TRAIL (Apo2L)

suppresses growth of primary human leukemia and myelodysplasia progenitors." in: **Leukemia**, Vol. 16, Issue 1, pp. 67-73, (2002) (PubMed).

### **Images**



#### **Apoptosis Detection**

Image 1. Induction of apoptosis Apoptosis induced in JURKAT human T cell leukemia cell line by soluble recombinant human TRAIL is completely blocked by antihuman TRAIL (2E5). The neutralizing activity of the antibody 2E5 has been confirmed with various sources of soluble recombinant human TRAIL. A - medium B - recombinant TRAIL C - recombinant TRAIL + anti-human TRAIL (2E5; 0.06 μg/ml) D - recombinant TRAIL + anti-human TRAIL (2E5; 0.24 μg/ml) E - recombinant TRAIL + Isotype mouse IgG1 control